TrialThe Journal of clinical investigation2024

Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study.

Wilson X Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.